{"disease":{"id":"lymphangioma","name":"Lymphangioma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"rapamune","indication_name":"Lymphangioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamune","company_name":"Wyeth is now a wholly owned subsidiary of Pfizer","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"rapamune","indication_name":"Lymphangiomatosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamune","company_name":"Wyeth is now a wholly owned subsidiary of Pfizer","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"sirolimus","indication_name":"Lymphangioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rapamune","generic_name":"sirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"mTOR Inhibitor Immunosuppressant [EPC]","quality_score":80,"revenue":null,"mechanism":"Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells."},{"drug_id":"sirolimus","indication_name":"Lymphangiomatosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rapamune","generic_name":"sirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"mTOR Inhibitor Immunosuppressant [EPC]","quality_score":80,"revenue":null,"mechanism":"Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells."},{"drug_id":"rapamycin","indication_name":"Lymphangioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamycin","company_name":"Institut National de la Santé Et de la Recherche Médicale, France","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rapamycin","indication_name":"Lymphangiomatosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamycin","company_name":"Institut National de la Santé Et de la Recherche Médicale, France","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06943703","title":"Bleomycin as an Effective and Curative Adjunct Therapy for Lymphangioma","phase":"","overall_status":"COMPLETED","enrollment_count":809,"lead_sponsor_name":"National Children's Hospital, Vietnam","has_results":false},{"nct_id":"NCT06892964","title":"Institution of an Italian Registry and Biobank for Biological Sample Collection","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07477548","title":"A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":67,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT02156115","title":"Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders","phase":"","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT03941782","title":"Compassionate Use of BYL 719 Alpelisib","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"New Mexico Cancer Research Alliance","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}